{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:54:03Z","timestamp":1790420043154,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T00:00:00Z","timestamp":1562630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.ymgme.2019.06.008","type":"journal-article","created":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T19:35:19Z","timestamp":1562096119000},"page":"355-360","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Enzyme replacement therapy initiated in adulthood: Findings from the mucopolysaccharidosis VI Clinical Surveillance Program"],"prefix":"10.1016","volume":"127","author":[{"given":"Christina","family":"Lampe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Harmatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Parini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa Le\u00e3o","family":"Teles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"Sivam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zlatko","family":"Sisic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2019.06.008_bb0005","first-page":"22","article-title":"Mucopolysaccharidosis VI: pathophysiology, diagnosis and treatment","volume":"21","author":"Harmatz","year":"2017","journal-title":"Front. Biosci."},{"key":"10.1016\/j.ymgme.2019.06.008_bb0010","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s10545-011-9410-9","article-title":"Design, baseline characteristics, and early findings of the MPS VI (mucopolysaccharidosis VI) clinical surveillance program (CSP)","volume":"36","author":"Hendriksz","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2019.06.008_bb0015","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1750-1172-5-5","article-title":"Mucopolysaccharidosis VI","volume":"5","author":"Valayannopoulos","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2019.06.008_bb0020","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1542\/peds.2006-2184","article-title":"Management guidelines for mucopolysaccharidosis VI","volume":"120","author":"Giugliani","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2019.06.008_bb0025","doi-asserted-by":"crossref","first-page":"956","DOI":"10.2174\/138920111795542688","article-title":"Recent advances in treatment approaches of mucopolysaccharidosis VI","volume":"12","author":"Giugliani","year":"2011","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.ymgme.2019.06.008_bb0030","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ymgme.2008.04.001","article-title":"Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase","volume":"94","author":"Harmatz","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2019.06.008_bb0035","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s10545-009-9007-8","article-title":"Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase","volume":"33","author":"Harmatz","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2019.06.008_bb0040","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jpeds.2004.03.018","article-title":"Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)","volume":"144","author":"Harmatz","year":"2004","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2019.06.008_bb0045","doi-asserted-by":"crossref","first-page":"e681","DOI":"10.1542\/peds.2004-1023","volume":"115","author":"Harmatz","year":"2005","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2019.06.008_bb0050","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jpeds.2005.12.014","volume":"148","author":"Harmatz","year":"2006","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2019.06.008_bb0055","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1002\/ajmg.a.36584","article-title":"Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)-10-year follow-up of patients who previously participated in an MPS VI survey study","volume":"164A","author":"Giugliani","year":"2014","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.ymgme.2019.06.008_bb0060","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ejim.2016.05.017","article-title":"Unique medical issues in adult patients with mucopolysaccharidoses","volume":"34","author":"Mitchell","year":"2016","journal-title":"Eur. J. Int. Med."},{"key":"10.1016\/j.ymgme.2019.06.008_bb0065","first-page":"1","article-title":"Long-term galsulfase treatment associated with improved survival of patients with mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): 15 year follow-up from the survey study","volume":"6","author":"Quartel","year":"2018","journal-title":"JIEMS"},{"key":"10.1016\/j.ymgme.2019.06.008_bb0070","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/ajmg.a.30579","article-title":"Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)","volume":"134A","author":"Swiedler","year":"2005","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.ymgme.2019.06.008_bb0075","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.rmed.2006.01.001","article-title":"Reference values for the 6-min walk test in healthy subjects 20-50 years old","volume":"100","author":"Chetta","year":"2006","journal-title":"Respir. Med."},{"key":"10.1016\/j.ymgme.2019.06.008_bb0080","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s10545-012-9474-1","article-title":"Clinical characteristics of adults with slowly progressing mucopolysaccharidosis VI: a case series","volume":"35","author":"Th\u00fcmler","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2019.06.008_bb0085","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/ped.12281","article-title":"Mucopolysaccharidosis type VI in Russia, Kazakhstan, and central and Eastern Europe","volume":"56","author":"Jurecka","year":"2014","journal-title":"Pediatr. Int."},{"key":"10.1016\/j.ymgme.2019.06.008_bb0090","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s00431-008-0910-z","article-title":"Mucopolysaccharidosis VI: the Italian experience","volume":"168","author":"Scarpa","year":"2009","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgme.2019.06.008_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2016.08.033","article-title":"Outcomes of long-term treatment with laronidase in patients with mucopolysaccharidosis type I","volume":"178","author":"Laraway","year":"2016","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2019.06.008_bb0100","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1167\/iovs.16-20647","article-title":"Objective quantification of changes in corneal clouding over time in patients with mucopolysaccharidosis","volume":"58","author":"Javed","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ymgme.2019.06.008_bb0105","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s10545-012-9481-2","article-title":"Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme\u00ae) therapy","volume":"36","author":"Braunlin","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2019.06.008_bb0110","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ymgme.2012.02.005","article-title":"Expert recommendations for the laboratory diagnosis of MPS VI","volume":"106","author":"Wood","year":"2012","journal-title":"Mol. Genet. Metab."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719219302379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719219302379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,22]],"date-time":"2019-09-22T13:39:49Z","timestamp":1569159589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719219302379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S1096719219302379"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2019.06.008","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enzyme replacement therapy initiated in adulthood: Findings from the mucopolysaccharidosis VI Clinical Surveillance Program","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2019.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}